Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transcript : Astellas Pharma Inc., Q1 2023 Earnings Call, Aug 01, 2022

08/01/2022 | 03:00am EDT
[Interpreted] Thank you very much. This is the FY '22 first quarter financial results announcement. I'm Ikeda from Corporate Advocacy relationship. I would like to service as moderator for this...


© S&P Capital IQ 2022
All news about ASTELLAS PHARMA INC.
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
AQ
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
MT
09/12Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
CI
09/04Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
CI
08/18Astellas Pharma Gets US FDA Nod on New Drug Application for Menopause
MT
08/18ADRs End Lower, Geely Automobile Trades Actively
DJ
08/18U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
CI
08/10Verizon Business selected to transform Astellas Pharma's global network infrastructure
AQ
08/10Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
MT
08/09Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovati..
AQ
More news
Financials
Sales 2023 1 454 B 10 075 M 10 075 M
Net income 2023 206 B 1 426 M 1 426 M
Net cash 2023 395 B 2 738 M 2 738 M
P/E ratio 2023 16,6x
Yield 2023 3,18%
Capitalization 3 451 B 23 910 M 23 910 M
EV / Sales 2023 2,10x
EV / Sales 2024 1,92x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 1 889,00 JPY
Average target price 2 596,15 JPY
Spread / Average Target 37,4%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.1.82%24 298
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.76%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392